PDGFRA and gastrointestinal stromal tumor: In real-world clinical practice, avapritinib is expected to be used as a first-line TKI for this indication, hence, it will be crucial to collect and publish data evaluating avapritinib in the first-line setting for unresectable/metastatic PDGFRA D842V-mutant GIST.